Development of a recombinant cell-based system for the characterisation of phosphodiesterase 4 isoforms and evaluation of inhibitors
- 19 May 1999
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 57 (12), 1375-1382
- https://doi.org/10.1016/s0006-2952(99)00062-3
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Isolation and Characterization of PDE9A, a Novel Human cGMP-specific PhosphodiesteraseJournal of Biological Chemistry, 1998
- Identification and Characterization of a Novel Family of Cyclic Nucleotide PhosphodiesterasesJournal of Biological Chemistry, 1998
- Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 1998
- Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.Proceedings of the National Academy of Sciences, 1995
- Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammationClinical and Experimental Immunology, 1995
- The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitisNature Medicine, 1995
- Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?Biochemical Pharmacology, 1992
- Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and functionPharmacology & Therapeutics, 1991
- Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.Thorax, 1991
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990